Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Petlife Pharmaceuticals 14-Day RSI Related Terms
PTLF vs PCYN, YBAO, BKIT: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petlife Pharmaceuticals 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Petlife Pharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petlife Pharmaceuticals (PTLF) has a 14-Day RSI of 100.00 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' 14-Day RSI too high?
Petlife Pharmaceuticals' current 14-Day RSI is 100.00. The Drug Manufacturers industry median 14-Day RSI is 47.35. Petlife Pharmaceuticals' value of 100.00 is 111.2% above this industry median.
How does Petlife Pharmaceuticals' 14-Day RSI compare to PCYN and YBAO?
Petlife Pharmaceuticals' 14-Day RSI of 100.00 can be compared against companies in the Drug Manufacturers industry. The industry median 14-Day RSI is 47.35. Petlife Pharmaceuticals' value of 100.00 is 111.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 47.35, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petlife Pharmaceuticals's current 14-Day RSI of 100.00 is 111.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 47.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current 14-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current 14-Day RSI of 100.00. The current 14-Day RSI is 100.00 and 111.2% above the Drug Manufacturers industry median of 47.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current 14-Day RSI is 100.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLF has been successfully added to your 
